<p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 的股價在週四交易前出現下跌。該股票此前收於 58.00 美元，但開盤價為 53.37 美元。Hims
&amp; Hers Health 的股票最後交易價格為 54.38 美元，成交量為 15,902,838 股。</p>
<p>獲取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>Hims
&amp; Hers 股票在 UnitedHealth 拋售後會好嗎？</li>
</ul>
<p>HIMS 已經成為多份研究分析報告的主題。瑞銀集團在 5 月 6 日的研究報告中重申了對 Hims
&amp; Hers Health 股票的 “混合” 評級。Canaccord Genuity Group 將 Hims
&amp; Hers Health 的目標價格從 38.00 美元上調至 68.00 美元，並在 2 月 19 日的研究報告中給予該公司 “買入” 評級。Needham
&amp; Company LLC 在 5 月 6 日的研究報告中重新發布了 “買入” 評級，並設定了 61.00 美元的目標價格。花旗集團在 5 月 6 日的報告中重申了 “賣出” 評級，並將 Hims
&amp; Hers Health 的目標價格設定為 30.00 美元（之前為 25.00 美元）。最後，Piper Sandler 在 5 月 6 日的研究報告中重申了 “中性” 評級，並將目標價格上調至 39.00 美元（之前為 35.00 美元）。兩位投資分析師對該股票給予了賣出評級，八位分析師給予了持有評級，四位分析師給予了買入評級。根據 MarketBeat 的數據，Hims
&amp; Hers Health 的共識評級為 “持有”，共識目標價格為 37.67 美元。</p>
<p>** 閲讀我們對 Hims
&amp; Hers Health 的最新分析 **</p>
<h2>Hims</h2>
<p>&amp; Hers Health 股票下跌 3.0%</p>
<ul>
<li>Hims
&amp; Hers 股票圖表顯示強勁的牛市延續</li>
</ul>
<p>該股票的市值為 125.9 億美元，市盈率為 127.74，貝塔值為 1.84。該公司的 50 日簡單移動平均線為 37.10 美元，200 日簡單移動平均線為 34.54 美元。</p>
<p>Hims
&amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近在 5 月 5 日發佈了季度財報。該公司報告本季度每股收益為 0.20 美元，超出市場共識預期的 0.12 美元，超出幅度為 0.08 美元。該公司本季度的收入為 5.8601 億美元，而分析師預期為 5.3521 億美元。Hims
&amp; Hers Health 的淨利潤率為 8.19%，股本回報率為 10.97%。該公司的收入同比增長了 110.7%。去年同期，該公司每股收益為 0.05 美元。平均而言，賣方分析師預測 Hims
&amp; Hers Health, Inc.在當前年度的每股收益將為 0.29 美元。</p>
<h2>內部人士下注</h2>
<ul>
<li>Hims
&amp; Hers 股票因基本面和擠壓潛力而上漲</li>
</ul>
<p>在相關消息中，內部人士 Patrick Harrison Carroll 在 3 月 18 日的交易中出售了 23,287 股該公司的股票。該股票以平均價格 34.31 美元出售，總價值為 798,976.97 美元。交易後，內部人士現在擁有 209,661 股公司股票，價值為 7,193,468.91 美元。這筆交易代表其持股減少了 10.00%。該交易已在證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，首席財務官 Oluyemi Okupe 在 5 月 15 日的交易中出售了 11,581 股公司的股票。該股票以平均價格 60.22 美元出售，總交易額為 697,407.82 美元。出售後，首席財務官現在直接擁有 113,816 股公司的股票，價值約為 6,853,999.52 美元。這筆交易代表其持股減少了 9.24%。該出售的披露信息可以在這裏找到。在上個季度，內部人士共出售了 618,936 股公司股票，價值為 25,182,692 美元。當前公司股票的 13.71% 由公司內部人士持有。</p>
<h2>對 Hims</h2>
<p>&amp; Hers Health 的對沖基金看法</p>
<p>機構投資者和對沖基金最近對該公司的持倉進行了調整。Farallon Capital Management LLC 在第四季度將其在 Hims
&amp; Hers Health 的持倉增加了 64,338.5%。Farallon Capital Management LLC 現在擁有 8,377,000 股公司股票，價值為 202,556,000 美元，此前在該期間內又購買了 8,364,000 股。Arrowstreet Capital Limited Partnership 在第四季度將其在 Hims
&amp; Hers Health 的持股增加了 192.0%。Arrowstreet Capital Limited Partnership 現在擁有 6,304,202 股公司股票，價值為 152,436,000 美元，此前在上個季度又購買了 4,145,305 股。先鋒集團在第四季度將其在 Hims
&amp; Hers Health 的持股增加了 11.1%。先鋒集團現在擁有 20,257,116 股公司股票，價值為 489,817,000 美元，此前在該期間內又購買了 2,020,722 股。Nuveen LLC 在第一季度購買了 Hims
&amp; Hers Health 的新頭寸，價值約為 58,403,000 美元。最後，永榮香港資產管理有限公司在第四季度購買了 Hims
&amp; Hers Health 的新股份，價值為 41,104,000 美元。機構投資者和對沖基金目前持有公司股票的 63.52%。</p>
<h2>關於 Hims</h2>
<p>&amp; Hers Health</p>
<p>(獲取免費報告)</p>
<p>Hims
&amp; Hers Health, Inc.運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病學和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Hims
&amp; Hers Health 更好</li>
<li>內部人士出售的解釋：它能否影響你的投資選擇？</li>
<li>3 只長期投資者在任何市場中都能喜愛的買入持有股票</li>
<li>3 只值得購買的醫療保健分紅股票</li>
<li>這四位頂級投資者在第一季度購買了超過 600 萬股 Broadcom 股票</li>
<li>如何投資生物技術股票</li>
<li>買入低點？3 只有望大幅反彈的石油股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
<p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HIMS

<p>Hims & Hers Health（紐約證券交易所代碼：HIMS）股價從 58.00 美元跳空下跌至 53.37 美元，隨後交易，最終收於 54.38 美元，成交量為 15,902,838 股。分析師的評級不一，目標價格範圍在 30.00 美元至 68.00 美元之間。公司報告每股收益為 0.20 美元，超出預期，營收為 5.8601 億美元，同比增長 110.7%。內部人士最近出售了大量股份，而機構投資者則增加了持股。該股票的市值為 125.9 億美元，市場共識評級為 “持有”，目標價格為 37.67 美元</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $58.00, but opened at $53.37. Hims &amp; Hers Health shares last traded at $54.38, with a volume of 15,902,838 shares.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 的股價在週四交易前出現下跌。該股票此前收於 58.00 美元，但開盤價為 53.37 美元。Hims
&amp; Hers Health 的股票最後交易價格為 54.38 美元，成交量為 15,902,838 股。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Will Hims &amp; Hers Stock Be Okay After UnitedHealth's Sell-Off?</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims
&amp; Hers 股票在 UnitedHealth 拋售後會好嗎？</li>
</ul>
</div><p>HIMS has been the subject of several research analyst reports. UBS Group reiterated a &#34;mixed&#34; rating on shares of Hims &amp; Hers Health in a research note on Tuesday, May 6th. Canaccord Genuity Group increased their target price on shares of Hims &amp; Hers Health from $38.00 to $68.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, February 19th. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $61.00 target price on shares of Hims &amp; Hers Health in a research report on Tuesday, May 6th. Citigroup reaffirmed a &#34;sell&#34; rating and issued a $30.00 price target (up previously from $25.00) on shares of Hims &amp; Hers Health in a report on Tuesday, May 6th. Finally, Piper Sandler reiterated a &#34;neutral&#34; rating and issued a $39.00 price objective (up previously from $35.00) on shares of Hims &amp; Hers Health in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Hims &amp; Hers Health has a consensus rating of &#34;Hold&#34; and a consensus target price of $37.67.</p>
<div class="lb-trans"><p>HIMS 已經成為多份研究分析報告的主題。瑞銀集團在 5 月 6 日的研究報告中重申了對 Hims
&amp; Hers Health 股票的 “混合” 評級。Canaccord Genuity Group 將 Hims
&amp; Hers Health 的目標價格從 38.00 美元上調至 68.00 美元，並在 2 月 19 日的研究報告中給予該公司 “買入” 評級。Needham
&amp; Company LLC 在 5 月 6 日的研究報告中重新發布了 “買入” 評級，並設定了 61.00 美元的目標價格。花旗集團在 5 月 6 日的報告中重申了 “賣出” 評級，並將 Hims
&amp; Hers Health 的目標價格設定為 30.00 美元（之前為 25.00 美元）。最後，Piper Sandler 在 5 月 6 日的研究報告中重申了 “中性” 評級，並將目標價格上調至 39.00 美元（之前為 35.00 美元）。兩位投資分析師對該股票給予了賣出評級，八位分析師給予了持有評級，四位分析師給予了買入評級。根據 MarketBeat 的數據，Hims
&amp; Hers Health 的共識評級為 “持有”，共識目標價格為 37.67 美元。</p>
</div><p><strong>Read Our Latest Analysis on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p>** 閲讀我們對 Hims
&amp; Hers Health 的最新分析 **</p>
</div><h2>Hims &amp; Hers Health Stock Down 3.0%</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 股票下跌 3.0%</p>
</div><ul>
<li>Hims &amp; Hers Stock Chart Points to Strong Bullish Continuation</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims
&amp; Hers 股票圖表顯示強勁的牛市延續</li>
</ul>
</div><p>The stock has a market capitalization of $12.59 billion, a P/E ratio of 127.74 and a beta of 1.84. The business has a 50-day simple moving average of $37.10 and a two-hundred day simple moving average of $34.54.</p>
<div class="lb-trans"><p>該股票的市值為 125.9 億美元，市盈率為 127.74，貝塔值為 1.84。該公司的 50 日簡單移動平均線為 37.10 美元，200 日簡單移動平均線為 34.54 美元。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims &amp; Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company's revenue was up 110.7% on a year-over-year basis. During the same quarter last year, the business posted $0.05 earnings per share. On average, sell-side analysts forecast that Hims &amp; Hers Health, Inc. will post 0.29 earnings per share for the current year.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近在 5 月 5 日發佈了季度財報。該公司報告本季度每股收益為 0.20 美元，超出市場共識預期的 0.12 美元，超出幅度為 0.08 美元。該公司本季度的收入為 5.8601 億美元，而分析師預期為 5.3521 億美元。Hims
&amp; Hers Health 的淨利潤率為 8.19%，股本回報率為 10.97%。該公司的收入同比增長了 110.7%。去年同期，該公司每股收益為 0.05 美元。平均而言，賣方分析師預測 Hims
&amp; Hers Health, Inc.在當前年度的每股收益將為 0.29 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><ul>
<li>Hims &amp; Hers Stock Rises on Fundamentals and Squeeze Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims
&amp; Hers 股票因基本面和擠壓潛力而上漲</li>
</ul>
</div><p>In related news, insider Patrick Harrison Carroll sold 23,287 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total value of $798,976.97. Following the transaction, the insider now owns 209,661 shares in the company, valued at $7,193,468.91. This trade represents a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $60.22, for a total transaction of $697,407.82. Following the sale, the chief financial officer now directly owns 113,816 shares of the company's stock, valued at approximately $6,853,999.52. This trade represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 618,936 shares of company stock valued at $25,182,692. 13.71% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Patrick Harrison Carroll 在 3 月 18 日的交易中出售了 23,287 股該公司的股票。該股票以平均價格 34.31 美元出售，總價值為 798,976.97 美元。交易後，內部人士現在擁有 209,661 股公司股票，價值為 7,193,468.91 美元。這筆交易代表其持股減少了 10.00%。該交易已在證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，首席財務官 Oluyemi Okupe 在 5 月 15 日的交易中出售了 11,581 股公司的股票。該股票以平均價格 60.22 美元出售，總交易額為 697,407.82 美元。出售後，首席財務官現在直接擁有 113,816 股公司的股票，價值約為 6,853,999.52 美元。這筆交易代表其持股減少了 9.24%。該出售的披露信息可以在這裏找到。在上個季度，內部人士共出售了 618,936 股公司股票，價值為 25,182,692 美元。當前公司股票的 13.71% 由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>對 Hims</h2>
<p>&amp; Hers Health 的對沖基金看法</p>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the company. Farallon Capital Management LLC raised its position in shares of Hims &amp; Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in Hims &amp; Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter. Vanguard Group Inc. raised its holdings in Hims &amp; Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after buying an additional 2,020,722 shares during the period. Nuveen LLC bought a new position in Hims &amp; Hers Health in the first quarter valued at approximately $58,403,000. Finally, Yong Rong HK Asset Management Ltd bought a new stake in Hims &amp; Hers Health in the 4th quarter valued at $41,104,000. Institutional investors and hedge funds own 63.52% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近對該公司的持倉進行了調整。Farallon Capital Management LLC 在第四季度將其在 Hims
&amp; Hers Health 的持倉增加了 64,338.5%。Farallon Capital Management LLC 現在擁有 8,377,000 股公司股票，價值為 202,556,000 美元，此前在該期間內又購買了 8,364,000 股。Arrowstreet Capital Limited Partnership 在第四季度將其在 Hims
&amp; Hers Health 的持股增加了 192.0%。Arrowstreet Capital Limited Partnership 現在擁有 6,304,202 股公司股票，價值為 152,436,000 美元，此前在上個季度又購買了 4,145,305 股。先鋒集團在第四季度將其在 Hims
&amp; Hers Health 的持股增加了 11.1%。先鋒集團現在擁有 20,257,116 股公司股票，價值為 489,817,000 美元，此前在該期間內又購買了 2,020,722 股。Nuveen LLC 在第一季度購買了 Hims
&amp; Hers Health 的新頭寸，價值約為 58,403,000 美元。最後，永榮香港資產管理有限公司在第四季度購買了 Hims
&amp; Hers Health 的新股份，價值為 41,104,000 美元。機構投資者和對沖基金目前持有公司股票的 63.52%。</p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>關於 Hims</h2>
<p>&amp; Hers Health</p>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc.運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病學和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1</li>
<li>How to Invest in Biotech Stocks</li>
<li>Buy the Dip? 3 Oil Stocks Poised for a Big Comeback</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Hims
&amp; Hers Health 更好</li>
<li>內部人士出售的解釋：它能否影響你的投資選擇？</li>
<li>3 只長期投資者在任何市場中都能喜愛的買入持有股票</li>
<li>3 只值得購買的醫療保健分紅股票</li>
<li>這四位頂級投資者在第一季度購買了超過 600 萬股 Broadcom 股票</li>
<li>如何投資生物技術股票</li>
<li>買入低點？3 只有望大幅反彈的石油股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Hims & Hers Health（紐約證券交易所代碼：HIMS）股價跳空下跌 - 以下是原因